Investigating the impact of the inflammatory immune microenvironment and steroids or COX-2 inhibitors usage on immunotherapy in advanced esophageal squamous cell carcinoma (ESCC): a propensity score matched analysis
Clinical and Translational Oncology · 2024
DOI: 10.1007/s12094-024-03668-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Huihui Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, 507 Zhengmin Road, Yangpu District, Shanghai, 20…. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Cyclooxygenase 2 Inhibitors, Tumor Microenvironment. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Zhejiang Provincial Natural Science Foundation of China, Program of Zhejiang Provincial TCM Sci-Tech Plan, Beijing Xisike Clinical Oncology Research Foundation.
Abstract (Originalsprache)
PURPOSE: The research aimed to evaluate the connection between pre-treatment inflammatory biomarkers and clinical results in advanced esophageal squamous cell carcinoma (ESCC) receiving immune checkpoint inhibitors. MATERIALS AND METHODS: Between 2019 and 2022, we analyzed 354 individuals diagnosed with metastatic ESCC who underwent immunotherapy. The study sought to evaluate the impact of specific inflammatory biomarkers (Neutrophil/Lymphocyte Ratio (NLR), C-reactive protein to albumin ratio (CRP/ALB) and Glasgow Prognostic Score (GPS), Cyclooxygenase-2 (COX-2) inhibitors or steroids usage on the effectiveness and survival outcomes of immunotherapy in advanced ESCC. The research utilized Kaplan‒Meier and Cox regression models alongside propensity score matching for analysis. RESULTS: The findings revealed that elevated pre-treatment NLR (11.0 vs. 14.6 months, p = 0.021) and CRP/ALB (11.4 vs. 14.6 months, p = 0.022) levels were significantly associated with poorer overall survival (OS) outcomes, while the use of steroids did not show a significant difference in OS (15.5 vs. 15.4 months, p = 0.685) between groups. Similarly, no notable disparity in OS was observed between patients treated withCOX-2 inhibitors and those who were not (13.8 vs. 11.0 months, p = 0.054). CONCLUSION: Lower levels of NLR and CRP/ALB prior to treatment were linked to better effectiveness and OS in immunotherapy for advanced ESCC. The study did not identify a significant relationship between OS in patients with esophageal cancer and the use of either steroids or COX-2 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, 507 Zhengmin Road, Yangpu District, Shanghai, 200433, China.
- Postgraduate Training Base Alliance, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
- Department of Medical Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, No. 1 Banshan East Road, Gongshu District, Hangzhou, 310022, Zhejiang, China.
- Department of Oncology, The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
- Department of Medical Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, No. 1 Banshan East Road, Gongshu District, Hangzhou, 310022, Zhejiang, China. fanyun1…
- Department of Oncology, The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310053, China. fanyun1218@163.com.
Förderung
- Zhejiang Provincial Natural Science Foundation of China
- Program of Zhejiang Provincial TCM Sci-Tech Plan
- Beijing Xisike Clinical Oncology Research Foundation
Zitieren
APA
Li, H., Chen, N., Wang, W., Ye, L., Fan, Y., & Xu, X. (2024). Investigating the impact of the inflammatory immune microenvironment and steroids or COX-2 inhibitors usage on immunotherapy in advanced esophageal squamous cell carcinoma (ESCC): a propensity score matched analysis. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03668-1
Vancouver
Li H, Chen N, Wang W, Ye L, Fan Y, Xu X. Investigating the impact of the inflammatory immune microenvironment and steroids or COX-2 inhibitors usage on immunotherapy in advanced esophageal squamous cell carcinoma (ESCC): a propensity score matched analysis. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03668-1
BibTeX
@article{Li2024,
author = {Li, Huihui and Chen, Ning and Wang, Wenjing and Ye, Lisha and Fan, Yun and Xu, Xiaoling},
title = {Investigating the impact of the inflammatory immune microenvironment and steroids or COX-2 inhibitors usage on immunotherapy in advanced esophageal squamous cell carcinoma (ESCC): a propensity score matched analysis},
journal = {Clinical and Translational Oncology},
year = {2024},
doi = {10.1007/s12094-024-03668-1}
}
EUVIMED